Ryman Healthcare Limited

NZSE:RYM Stock Report

Market Cap: NZ$3.0b

Ryman Healthcare Future Growth

Future criteria checks 4/6

Ryman Healthcare is forecast to grow earnings and revenue by 27.4% and 9.2% per annum respectively. EPS is expected to grow by 22.3% per annum. Return on equity is forecast to be 6.2% in 3 years.

Key information

27.4%

Earnings growth rate

22.3%

EPS growth rate

Healthcare earnings growth12.5%
Revenue growth rate9.2%
Future return on equity6.2%
Analyst coverage

Low

Last updated02 Dec 2024

Recent future growth updates

Recent updates

Is Ryman Healthcare Limited (NZSE:RYM) Trading At A 42% Discount?

Nov 25
Is Ryman Healthcare Limited (NZSE:RYM) Trading At A 42% Discount?

Is Ryman Healthcare (NZSE:RYM) Weighed On By Its Debt Load?

Aug 16
Is Ryman Healthcare (NZSE:RYM) Weighed On By Its Debt Load?

Are Investors Undervaluing Ryman Healthcare Limited (NZSE:RYM) By 47%?

Jul 12
Are Investors Undervaluing Ryman Healthcare Limited (NZSE:RYM) By 47%?

Ryman Healthcare's (NZSE:RYM) Soft Earnings Don't Show The Whole Picture

Jun 05
Ryman Healthcare's (NZSE:RYM) Soft Earnings Don't Show The Whole Picture

Little Excitement Around Ryman Healthcare Limited's (NZSE:RYM) Earnings

May 21
Little Excitement Around Ryman Healthcare Limited's (NZSE:RYM) Earnings

Returns On Capital At Ryman Healthcare (NZSE:RYM) Paint A Concerning Picture

Apr 24
Returns On Capital At Ryman Healthcare (NZSE:RYM) Paint A Concerning Picture

Ryman Healthcare Limited's (NZSE:RYM) P/E Is On The Mark

Feb 08
Ryman Healthcare Limited's (NZSE:RYM) P/E Is On The Mark

Here's Why Ryman Healthcare (NZSE:RYM) Has A Meaningful Debt Burden

Jan 07
Here's Why Ryman Healthcare (NZSE:RYM) Has A Meaningful Debt Burden

Capital Allocation Trends At Ryman Healthcare (NZSE:RYM) Aren't Ideal

Dec 20
Capital Allocation Trends At Ryman Healthcare (NZSE:RYM) Aren't Ideal

What Is Ryman Healthcare Limited's (NZSE:RYM) Share Price Doing?

Sep 11
What Is Ryman Healthcare Limited's (NZSE:RYM) Share Price Doing?

Ryman Healthcare (NZSE:RYM) Has Debt But No Earnings; Should You Worry?

Jul 04
Ryman Healthcare (NZSE:RYM) Has Debt But No Earnings; Should You Worry?

Ryman Healthcare Limited (NZSE:RYM) Shares Could Be 24% Below Their Intrinsic Value Estimate

May 30
Ryman Healthcare Limited (NZSE:RYM) Shares Could Be 24% Below Their Intrinsic Value Estimate

Should You Think About Buying Ryman Healthcare Limited (NZSE:RYM) Now?

Aug 26
Should You Think About Buying Ryman Healthcare Limited (NZSE:RYM) Now?

When Should You Buy Ryman Healthcare Limited (NZSE:RYM)?

May 04
When Should You Buy Ryman Healthcare Limited (NZSE:RYM)?

What Is Ryman Healthcare Limited's (NZSE:RYM) Share Price Doing?

Jan 08
What Is Ryman Healthcare Limited's (NZSE:RYM) Share Price Doing?

Investors Could Be Concerned With Ryman Healthcare's (NZSE:RYM) Returns On Capital

Oct 14
Investors Could Be Concerned With Ryman Healthcare's (NZSE:RYM) Returns On Capital

Is It Too Late To Consider Buying Ryman Healthcare Limited (NZSE:RYM)?

Sep 14
Is It Too Late To Consider Buying Ryman Healthcare Limited (NZSE:RYM)?

Is Ryman Healthcare (NZSE:RYM) Using Too Much Debt?

Aug 04
Is Ryman Healthcare (NZSE:RYM) Using Too Much Debt?

Should You Think About Buying Ryman Healthcare Limited (NZSE:RYM) Now?

May 22
Should You Think About Buying Ryman Healthcare Limited (NZSE:RYM) Now?

Is Ryman Healthcare Limited (NZSE:RYM) A Good Fit For Your Dividend Portfolio?

Apr 17
Is Ryman Healthcare Limited (NZSE:RYM) A Good Fit For Your Dividend Portfolio?

Should You Review Recent Insider Transactions At Ryman Healthcare Limited (NZSE:RYM)?

Mar 20
Should You Review Recent Insider Transactions At Ryman Healthcare Limited (NZSE:RYM)?

Our Take On The Returns On Capital At Ryman Healthcare (NZSE:RYM)

Mar 07
Our Take On The Returns On Capital At Ryman Healthcare (NZSE:RYM)

Do Institutions Own Ryman Healthcare Limited (NZSE:RYM) Shares?

Feb 23
Do Institutions Own Ryman Healthcare Limited (NZSE:RYM) Shares?

Returns On Capital At Ryman Healthcare (NZSE:RYM) Paint An Interesting Picture

Nov 23
Returns On Capital At Ryman Healthcare (NZSE:RYM) Paint An Interesting Picture

Earnings and Revenue Growth Forecasts

NZSE:RYM - Analysts future estimates and past financials data (NZD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
3/31/20278884381126012
3/31/20268193593317082
3/31/2025741345-2515972
9/30/2024720-88374608N/A
6/30/2024704-42376633N/A
3/31/20246885379658N/A
12/31/2023669128380693N/A
9/30/2023640251363732N/A
6/30/2023611254281687N/A
3/31/2023582258199642N/A
12/31/2022558432139585N/A
9/30/202253560580529N/A
6/30/2022522649158557N/A
3/31/2022509693237586N/A
12/31/2021495593291602N/A
9/30/2021481492345618N/A
6/30/2021469458246515N/A
3/31/2021456423147413N/A
12/31/2020447356104352N/A
9/30/202043828960290N/A
6/30/2020431277100370N/A
3/31/2020423265140450N/A
12/31/2019413305148445N/A
9/30/2019402345155440N/A
6/30/2019392335184421N/A
3/31/2019382326213401N/A
12/31/2018373341200397N/A
9/30/2018364355188392N/A
6/30/2018353372N/A371N/A
3/31/2018342388N/A349N/A
12/31/2017329380N/A343N/A
9/30/2017315372N/A337N/A
6/30/2017302365N/A330N/A
3/31/2017289357N/A323N/A
12/31/2016281358N/A320N/A
9/30/2016273360N/A316N/A
6/30/2016266333N/A314N/A
3/31/2016260305N/A312N/A
12/31/2015252286N/A294N/A
9/30/2015244267N/A276N/A
6/30/2015235254N/A255N/A
3/31/2015226242N/A234N/A
12/31/2014219233N/A236N/A
9/30/2014212224N/A237N/A
6/30/2014207210N/A238N/A
3/31/2014203195N/A238N/A
12/31/2013197171N/A234N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: RYM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (3%).

Earnings vs Market: RYM is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RYM is expected to become profitable in the next 3 years.

Revenue vs Market: RYM's revenue (9.2% per year) is forecast to grow faster than the NZ market (4.4% per year).

High Growth Revenue: RYM's revenue (9.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: RYM's Return on Equity is forecast to be low in 3 years time (6.2%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 10:11
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Ryman Healthcare Limited is covered by 9 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew SteeleCredit Suisse
Stephen RidgewellDeutsche Bank
Aaron IbbotsonForsyth Barr Group Ltd.